Crovalimab (anti-Complement C5) (C007B-446394)

Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab (anti-Complement C5) can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab (anti-Complement C5) inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab (anti-Complement C5) has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.Purity:>95% (SDS-PAGE&SEC):Endotoxin Level:< 1.0EU/mg. Specification: ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot

UPC:

41181519

Condition:

New

Weight:

1.09 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

Ab182862-5mg

CAS:

1917321-26-6

Product Size:

5mg